(Q36832116)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Michele Orditura

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Teresa Troiani

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Fortunato Ciardiello

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

E Lieto

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

F De Vita

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

P Castellano

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

V Imperatore

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

language of work or name

English

0 references

publication date

1 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

3654-3660

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530019%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210381

31 December 2019

exact match

0 references

cites work

Somatic mutations of EGFR in colorectal cancers and glioblastomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

New systemic frontline treatment for metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

Anti-epidermal growth factor receptor drugs in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

Epidermal growth factor receptor biology (IMC-C225).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

The epidermal growth factor receptor as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

7 January 2021

Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

7 January 2021

Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative Surgery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

7 January 2021

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

7 January 2021

Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

7 January 2021

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

7 January 2021

Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210381

7 January 2021